Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.01 | 0.00 | -0.31 |
| FCF Yield | 114.48% | -0.06% | 0.05% | -107.98% |
| EV / EBITDA | 9.81 | 15.29 | 22.31 | 8.50 |
| Quality | ||||
| ROIC | 4.66% | 13.18% | 4.69% | 3.75% |
| Gross Margin | 56.39% | 58.40% | 59.98% | 58.47% |
| Cash Conversion Ratio | -3.84 | 0.32 | -0.32 | -12.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.62% | 4.16% | 14.87% | 2,983,065.52% |
| Free Cash Flow Growth | 182.99% | -481.66% | 100.03% | 0.30% |
| Safety | ||||
| Net Debt / EBITDA | 9.81 | 13.28 | 21.08 | 7.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.42 |
| Efficiency | ||||
| Inventory Turnover | 3.98 | 3.56 | 6.25 | 3.45 |
| Cash Conversion Cycle | 3.14 | -25.76 | -115.18 | 3.31 |